OncoMatch/Clinical Trials/NCT06268652
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Is NCT06268652 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Gemcitabine and Capecitabine for breast cancer.
Treatment: Gemcitabine · Capecitabine · Vinorelbine · Eribulin — This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
WBC ≥3 × 10^9/L; ANC ≥1.5 × 10^9/L; PLT ≥100 × 10^9/L; Hgb ≥8g/dL
Kidney function
serum creatinine clearance (CG formula) > 30 mL/min
Liver function
AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN (no liver invasion) or ≤ 5 × ULN (with liver invasion); total bilirubin (TBIL) ≤ ULN
Cardiac function
No serious organ (main organ: heart, lung, liver, kidney) functional abnormalities (refer to respective standards); Exclude NYHA Class III or IV heart failure, poorly controlled coronary artery disease or arrhythmia, or history of myocardial infarction within 6 months
No serious organ (main organ: heart, lung, liver, kidney) functional abnormalities (refer to respective standards); Routine blood test: white blood cells (WBC) ≥3 × 10^9/L; absolute neutrophil count (ANC) ≥1.5 × 10^9/L; platelets (PLT) ≥100 × 10^9/L; hemoglobin (Hgb) ≥8g /dL; Blood biochemical indicators: AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN (no liver invasion) or ≤ 5 × ULN (with liver invasion); total bilirubin (TBIL) ≤ ULN; serum creatinine clearance (CG formula) > 30 mL/min; Coagulation function: PT, INR ≤ 1.5 × ULN (unless warfarin is being used for anticoagulation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify